Separate terms with OR to return results that match either term.
 
Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name (Ascending) Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9117 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct. 1, 2002 Dec. 31, 2002 No Longer Used
C9118 Ibritumomab tiuxetan Zevalin Per MCI Immunotherapy Radioimmunotherapy CD20 No 2002 Oct. 1, 2002 Dec. 31, 2002 No Longer Used
C9058 Pegfilgrastim-bmez Ziextenzo 0.5mg Ancillary Therapy immunomodulatorne Granulocyte Colony Stimulating Factor No 2019 March 31, 2020 July 1, 2020 No Longer Used
Q5120 Pegfilgratim-bmez Ziextenzo 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2019 July 1, 2020 In Use
J1190 Dexrazoxane Zinecard 250 mg Ancillary Therapy Chemoprotective Detoxifying Agent No 1995 Jan. 1, 2007 In Use
Q5118 Bevacizumab-bvzr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct. 1, 2019 In Use
J2405 Ondansetron Zofran, Zofran ODT, Zuplenz 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 1991 Jan. 1, 1993 In Use
Q0179 Ondansetron Zofran, Zofran ODT, Zuplenz 8 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 April 1, 1998 Dec. 31, 2011 No Longer Used
Q0162 Ondansetron with active chemotherapy treatment adminstration Zofran, Zofran ODT, Zuplenz 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Jan. 1, 2012 In Use
S0181 Ondansetron Zofran, Zofran ODT, Zuplenz 4 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Jan. 1, 2002 Dec. 31, 2011 No Longer Used

Found 716 results in 2 milliseconds — Export these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.